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3q26.2 amplification in high-grade serous ovarian
cancer leads to increased expression of mature
microRNA miR551b-3p, which is associated with
poor clinical outcome. Importantly, miR551b-3p con-
tributes to resistance to apoptosis and increased
survival and proliferation of cancer cells in vitro
and in vivo. miR551b-3p upregulates STAT3 pro-
tein levels, and STAT3 is required for the effects
of miR551b-3p on cell proliferation. Rather than
decreasing levels of target mRNA as expected, we
demonstrate that miR551b-3p binds a complemen-
tary sequence on the STAT3 promoter, recruiting
RNA polymerase II and the TWIST1 transcription fac-
tor to activate STAT3 transcription, and thus directly
upregulates STAT3 expression. Furthermore, anti-
miR551b reduced STAT3 expression in ovarian can-
cer cells in vitro and in vivo and reduced ovarian can-
cer growth in vivo. Together, our data demonstrate a
role for miR551b-3p in transcriptional activation.
Thus, miR551b-3p represents a promising candidate
biomarker and therapeutic target in ovarian cancer.
INTRODUCTION
DNA copy-number alterations (CNAs) occur commonly in can-
cer. 3q26 amplification is a frequent event in high-grade serous
epithelial ovarian cancer (HGSEOC) (Bell et al., 2011; Chalu-
vally-Raghavan et al., 2014; Shayesteh et al., 1999), which is
the most common and aggressive form of ovarian cancer. We
have demonstrated that the 3q26 CNA is complex, resulting in
amplification and aberrant function of several oncogenes,Ce
This is an open access article under the CC BY-Nincluding PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-ki-
nase catalytic subunit alpha) (Shayesteh et al., 1999), PKCi
(Eder et al., 2005), Mecom (EVI1 and MDS1/EVI1) (Nanjundan
et al., 2007), and a non-coding RNA, miR569 (Chaluvally-Ragha-
van et al., 2014). While the coding genes in the 3q26.2 amplicon
are well studied, the potential roles of microRNAs (miRNAs)
located at the 3q26 locus remain poorly characterized. Thus,
it appears likely that the 3q26.2 amplicon contributes to
tumor pathophysiology through coordinate dysregulation ofmul-
tiple cellular functional processes as a consequence of altered
expression of coding and non-coding RNAs.
miRNAs are thought to primarily regulate cellular functions
through decreasing the stability or translation of multiple mRNAs
based on binding to ‘‘seed’’ sequences located at the 30 end of
the mRNA (Bartel, 2004). While a small set of studies suggest
that miRNA can increase gene transcription (Janowski et al.,
2007; Place et al., 2008), the underlying mechanisms remain to
be elucidated. Thus, miRNAs can directly increase or decrease
the expression of key regulatory proteins, as well as have sec-
ondary effects on multiple targets.
The signal transducer and activator 3 (STAT3) transcription
factor (TF) is constitutively activated in cancer cells, and high
levels of STAT3 are associated with poor outcome in ovarian
cancer patients (Rosen et al., 2006). STAT3 not only increases
proliferation of ovarian cancer cells but also engenders resis-
tance of stem cell-like cells to chemotherapy (Abubaker et al.,
2014). STAT3 has been explored as a potential target in ovarian
cancer models and has demonstrated utility in both monother-
apy and combination therapy (Ma et al., 2015; Wen et al., 2015).
In this study, we demonstrate that miR551b, which is located
near the peak of the 3q26.2 amplicon, is increased and is func-
tionally relevant in ovarian cancer, consistent with non-coding
RNAs and miRNAs located in the 3q26.2 locus acting as unex-
pected drivers in ovarian cancer. Our studies identified comple-
mentarity between miR551b-3p and sequences in the promoterll Reports 15, 1493–1504, May 17, 2016 ª 2016 The Authors 1493
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. 3q26.2 Amplification Correlates
with miR551b-3p Expression, and miR551b-
3p Increases Proliferation of Ovarian Cancer
Cells
(A) Copy-number status of genes located in the
3q26.2 locus in 489 ovarian cancer patients in the
TCGA SNP array dataset. Genes were arranged
based on the order in RefSeq (GRCh37/hg19,
2009). The core 3q26.2 amplicon is bounded by the
green lines.
(B) miR551b-3p expression was quantified in 24
ovarian cancer samples by real-time qPCR. Blue
(n = 8) and red (n = 16) boxes indicate 3q26.2
amplification status from SNP data.
(C) miRNAwas isolated from the indicated cell lines
in triplicate. miR551b-3p expression was assessed
by qRT-PCR and normalized to U6 RNA in breast
and ovarian cell lines. Bars represent SD of tripli-
cate determinations.
(D) miR551b-3p in situ hybridization was performed
in 145 HGSEOC tumor samples. Representative
samples from each group are displayed. Scale bar
represents 200 mm.
(E) Kaplan-Meier plot of overall survival of 145
ovarian cancer patients stratified by high (red,
combination of moderate and strong staining)
versus low (blue) miR551b-3p expression deter-
mined by RNA in situ hybridization. Log rank test
was used to compare differences between the two
groups.
(F) IGROV1 cells were grown on low-attachment
culture plates, and cells were transfected with
control (Con.) miR, miR551b-3p, or mutated
miR551b. Spheroids formedwere fixed and stained
with DAPI or anti-cleaved caspase-3. Scale bar
represents 50 mm.
(G and H) Cleaved caspase-3-positive cells (G)
were counted from three fields from three inde-
pendent experiments, as described in (F). Numbers
of spheroids formed (H) were quantified. Bars
represent SD of three experiments. *p < 0.001
compared to the Con. or mutated miR transfected
group. The p values were determined by Student’s
t test.of STAT3. miR551b-3p leads to recruitment of RNA polymerase
II (Pol II) and the TWIST1 TF to the STAT3 promoter and in-
creases STAT3 mRNA levels. Consistent with a key role of
miR551b-3p and STAT3 in ovarian cancer pathophysiology,
anti-miR551b incorporated into neutral nanoliposomes (Chalu-
vally-Raghavan et al., 2014; Landen et al., 2005) markedly
decreased ovarian cancer growth in vivo.
RESULTS
Increased Expression of miR551b-3p Is Associated with
Worsened Outcome in HGSEOC
Our analysis using high-resolution SNP array datasets from The
Cancer Genome Atlas (TCGA) demonstrated that miR551b is
locatedat theconsensuspeakof the3q26.2 locusand isamplified
in approximately one-third of patients with HGSEOC (Figure 1A).
Because two mature miRNAs, miR551b-5p and miR551b-3p,
arederived fromprecursormiR551b (pre-miR551b),weemployed1494 Cell Reports 15, 1493–1504, May 17, 2016TCGA ovarian cancer data to assess expression of miR551b
mature forms. Our analysis demonstrated miR551b-3p to be
highly expressed in tumors, whereas the mature miR551b-5p
was barely detectable (Figures S1A and S1B). Consistent with
the expression of miR551b-3p and miR551b-5p in TCGA data,
our qPCR results demonstrate that miR551b-3p is highly ex-
pressed in ovarian cancer cell lines compared to miR551b-5p
(Figure S1C). Thus, we focused on the functional roles andmech-
anism of action of miR551b-3p in the current study.
Analysis of two ovarian cancer patient cohorts demonstrated
that copy-number gain (>2.8 copies) or amplification (>4 copies)
of 3q26.2 is associated with increased miR551b-3p expression
(Figures 1B and S2A). Furthermore, miR551b-3p is highly ex-
pressed in tumor samples compared to normal ovarian tissue
(Figure S2B). Consistent with the patient data, miR551b-ampli-
fied cell lines exhibit high expression of miR551b-3p (Figure 1C).
We further assessed miR551b-3p expression using RNA in situ
hybridization in 145 HGSEOC samples (Figure 1D). Our analysis
demonstrates that miR551b-3p expression is associated with
poor outcome in HGSEOC (Figure 1E; Table S1), with approxi-
mately 40% of HGSEOC patients with low miR551b-3p demon-
strating long-term survival and all patients with high miR551b-3p
levels succumbing to their disease. Thus, amplification and
overexpression of miR551b-3p is associated with aggressive
HGSEOC and predicts patient outcome. Together, our results
suggest that miR551b-3p, the key mature form derived from
pre-miR551b, has an important role in the pathophysiology of
HGSEOC.
miR551b-3p Regulates Ovarian Cancer Cell Growth and
Survival In Vitro
Consistent with a role of miR551b-3p in the pathophysiology of
ovarian cancer, enforced expression of miR551b-3p in IGROV1
and HEYA8 ovarian cancer cells and immortalized ovarian
epithelial cells IOSE80 reduced apoptosis, as indicated by low
expression of cleaved caspase-3 and increased number and
size of spheroids formed in non-adherent culture conditions (Fig-
ures 1F–1H and S2C–S2E). In addition, miR551b-3p increased
proliferation of IGROV1, IOSE80, HEYA8, and MDAMB231 cells
in 2D adherent culture conditions (Figure S2F). Thus, the effects
of miR551b-3p on proliferation are generalizable across multiple
cell lines, encompassing both breast and ovarian lineages. In
contrast, miR551b-5p or mutated miR551b-3p did not alter
proliferation of ovarian cancer cells or immortalized ovarian
epithelial cells (Figure S2F), again supporting miR551b-3p as
the functionally relevant product of pre-miR551b.
miR551b-3p Increases TumorGrowth of Ovarian Cancer
Cells In Vivo
To determine whether miR551b-3p altered tumor growth in vivo,
nudemice bearing IGROV1 tumors were treated with intraperito-
neal injection of miR551b-3p incorporated in neutral 1,2-dio-
leoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes
(Chaluvally-Raghavan et al., 2014; Landen et al., 2005). Intraper-
itoneal injection of miR551b-3p into nude mice markedly
increased the number of tumor nodules and tumor weight
(Figures 2A–2D). Ascites formation is a common event in ovarian
carcinoma, particularly HGSEOC, and potentially contributes to
peritoneal seeding and poor patient outcomes (Mills et al., 1990,
1988). miR551b-3p increased ascites formation in mice bearing
IGROV1 cancer cells (Figures 2E–2G). Subsequently, we as-
sessed the viability of epithelial cancer cells isolated from perito-
neal fluid from IGROV1 tumor-bearing mice. Strikingly miR551b-
3p expressionmarkedly reduced the number of apoptotic cells in
ascites fluid (Figure 2H). As expected, immunohistochemical
analysis of tumor tissues from miR551b-3p-treated mice
demonstrated an increase in the number of Ki67-positive cells
and loss of cleaved caspase-3 expression, consistent with
proliferative and anti-apoptotic effects of miR551b-3p in vivo
(Figures 2I and 2J). In addition, miR551b-3p increased the
number of peritoneal implants in mice bearing IGROV1 tumors
(Figure 2K). Consistent with our results that miR55b-3p
increased ascites formation in animal models (Figures 2E–2G),
there is a significant association of miR551b-3p expression
with ascites formation in clinical samples of HGSEOC patients
(Table S2).Taken together, our results suggest that amplification and
subsequent high expression of miR551b-3p is a key event
contributing to survival and proliferation of ovarian cancer cells
in vitro and in vivo.
miR551b-3p Targets STAT3 Expression with
Subsequent Increases in Self-Renewal Capacity of
Spheroids
Weused fourprediction tools (RNA22,miRanda, Targetscan, and
miRwalk) to identify potential targets of miR551b-3p. To test
whether miR551b-3p alters levels of the 33 genes predicted
to be miR551b-3p targets (Figure S3A), we overexpressed
miR551b-3p in IGROV1 cells and performed qPCR to determine
levels of each potential target. Of the 33 potential targets, eight
genes (ATXN7, GPT, NDEL1, NTRK2, RPP15, SLC7A1, TCHH,
and WDFY4) were modestly downregulated (between 30% and
60%)uponmiR551b-3p expression (FigureS3B). To testwhether
the loss of expression of the eight potential miR551b-3p targets
(Figure S3C) could explain the biological effects of miR551b-
3p, we assessed the effect of knockdown of these genes on pro-
liferation and spheroid formation, which is markedly altered by
miR551b-3p in IGROV1 cells (Figures 1 and S1). In contrast
with the effects of miR551b-3p, knockdown of each of the eight
genes did not substantially alter either proliferation or spheroid
formation of IGROV1cells (FiguresS3D–S3G). These results sug-
gest that miR551b-3p could act through a mechanism indepen-
dent of binding to consensus sites in the 30 UTRs of target genes.
To identify potential functional consequences of miR551b-3p,
we employed reverse-phase protein arrays (RPPA) (Hennessy
et al., 2010), where we expressed miR551b-3p in IGROV1 and
SKOV3 ovarian cancer cells and IOSE80-immortalized ovarian
epithelial cells and assessed effects on the levels of 280 proteins
involved in cell signaling. Our analysis demonstrated that total
and phosphorylated (Y705) STAT3 are upregulated in all three
cell lines (Figure 3A). Consistent with our RPPA results, qPCR
demonstrated that miR551b-3p upregulated STAT3 mRNA in
SKOV3, IOSE80, and IGROV1 cells (Figure 3B). Furthermore,
immunoblotting showed that miR551b-amplified cancer cell
lines (Figure 1C) exhibit increased STAT3 protein levels (Fig-
ure 3C). Conversely, anti-miR551b decreases STAT3 levels in
HEYA8 and SKOV3 cells (Figure 3D), which express high levels
of miR551b-3p (Figure 1C) and concurrently reduces the number
of spheroids under matrix-deprived conditions (Figure 3E).
The ability of miR551b-3p to increase growth in non-adherent
cultures suggested that miR551b-3p could promote tumor-initi-
ating cell (TIC) or stem cell-like activity (Burgos-Ojeda et al.,
2012; Medema, 2013). Consistent with the effects of miR551b-
3p on STAT3 levels (Figures 3A and 3B), miR551b-3p increased
the number of IOSE80 and IGROV1 spheroids formed in serial
passages, which provides an in vitro surrogate for TIC and
stem cell-like activity (Figure 3F). Taken together, our data
demonstrate that the miR551b-STAT3 axis regulates multiple
oncogenic processes in ovarian cancer.
STAT3 Is Required for miR551b-Induced Proliferation
and Survival of Ovarian Cancer Cells
To determine whether the decrease in STAT3 induced by anti-
miR551b was responsible for the inhibition of proliferation andCell Reports 15, 1493–1504, May 17, 2016 1495
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Figure 2. miR551b-3p Increases Proliferation of Ovarian Cancer Cells In Vivo
(A–C) IGROV1 cells (13 106 cells/animal) were injected intraperitoneally. Mice were treated with control (Con.) miR ormiR551b-3p (n = 10 per group) twice weekly
for 5 weeks. Number of abdominal tumors (A) and tumor weight (C) were quantified at the end of the experiment. Representative images are displayed (B).
(D) miR551b-3p expression in tumor tissues described in Figure 1C was quantified by qPCR. miR551b-3p expression was normalized to U6 small RNA.
(E) Representative images of mice described in (A).
(F and G) Mice bearing ascites fluid were dissected and photographed (F). Ascites fluid volume was quantified (G).
(H) Epithelial cells from ascites fluid from three mice in each group were isolated and cell viability, was assessed by propidium iodide staining.
(legend continued on next page)
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spheroid formation, we stably reduced STAT3 expression using
two small hairpin RNAs (shRNAs) (Figure 4A). Consistent with
our results that anti-miR551b reduced STAT3 levels and
spheroid formation (Figures 3D and 3E), STAT3 shRNAmarkedly
decreased proliferation and spheroid formation in both HEYA8
and SKOV3 cells (Figures 4B and 4C). In cells with knockdown
of STAT3, anti-miR551b did not further decrease either prolifer-
ation or spheroid formation (Figures 4B and 4C). In conclusion,
our results demonstrate that the effects of miR551b-3p on cell
survival and proliferation are dependent on STAT3 as an interme-
diary factor.
To assess whether any of the eight genes identified as poten-
tial targets of miR551b-3p (Figure S3C) could explain the effect
of miR551b-3p on STAT3, we knocked down each of the eight
genes (ATXN7, GPT, NDEL1, NTRK2, RPP15, SLC7A1, TCHH,
and WDFY4) modestly downregulated by miR551b-3p (Fig-
ure S3C) and showed that this did not change STAT3 expression,
again suggesting that the effect ofmiR551b-3p on STAT3 is likely
independent of binding to 30 UTRs of target genes (Figures S4A
and S4B).
STAT3 Levels Correlate with Outcomes in Ovarian
Cancer
Consistent with the poor prognosis associated with high
miR551b-3p expression (Figure 1E), STAT3 expression by
immunohistochemistry (IHC) in 145 HGSEOC patient samples
demonstrated that high STAT3 expression was associated
with decreased overall survival of women with HGSEOC (Fig-
ures 4D and 4E; Table S1). Similarly, our analysis demonstrated
that increased STAT3 mRNA levels were associated with
decreased progression-free survival (Figure S4C) in an indepen-
dent cohort of ovarian cancer patients (Tothill et al., 2008).
Together, our data support the contention that miR55b-3p in-
duces STAT3 expression, which contributes to aggressiveness
of HGSEOC.
miR551b-3p Interacts with the STAT3 Promoter to
Increase STAT3 Transcription
miRNAs primarily elicit their effects by suppressing translation or
degradingmRNA throughRNAi (Ambros, 2001; Farh et al., 2005).
AlthoughmiRNAs can also target promoter regions and increase
transcription (Huang et al., 2012; Janowski et al., 2007; Place
et al., 2008), the mechanism or mechanisms by which miRNAs
activate transcription are not well understood. miR551b-3p
increased STAT3 promoter-driven luciferase activity, while
control miRs or mutant miR551b-3p did not increase lucif-
erase activity (Figure 5A), consistent with the contention that
miR551b-3p activates the STAT3 promoter. Surprisingly,
miR551b-3p demonstrated sequence complementarity with a
loop structure in the STAT3 promoter (Figure 5B). To determine
whether the miR551b-3p complementary sequences are critical
for miR551b-3p-induced STAT3 transcription, we mutated four
sites on the STAT3 promoter that could play a role in the action(I and J) IHCwas performed on tumor tissues from (A) using Ki67 and cleaved casp
three mice from each group. Scale bar represents 100 mm.
(K) Sites of tumor growth from mice in (A).
The p values were determined by Student’s t test.of miR551b-3p (sequences in the blue boxes in Figure 5B are
mutated as indicated in Figure 5C). Deletion of the loop structure
or sequences on either side of the loop structure abolished the
effects of miR551b-3p on STAT3 promoter-induced luciferase
activity (Figures 5C and 5D). However, mutations distant to the
loop structure (Mut1 in Figures 5C and 5D) did not block the ef-
fects of miR551b-3p expression on luciferase activity. Thus, the
core complementary sequences between miR551b-3p and the
STAT3 promoter are critical for the ability of miR551b-3p to
active the STAT3 promoter.
To identify TFs that bind in the region of the STAT3 promoter
with complementarity to miR551b-3p, we employed Genomatix
Matinspector software. We then knocked down the expression
of each candidate TF, demonstrating that knockdown of
TWIST1 but not other candidates, with the exception of
STAT5B, abrogated the effects of miR551b-3p on the STAT3
promoter (Figure 5E). Neither TWIST1 nor STAT5B knockdown
altered basal (i.e., non-miR551b-3p mediated) promoter
activity.
miR551b-3p Recruits Pol II to the STAT3 Promoter
miRNAs that increase transcription have been shown to be part
of a complex with Argonaute proteins and the Pol II transcription
machinery (Zhang et al., 2014). To determine whether miR551b-
3p associates with Pol II on the STAT3 promoter, we biotinylated
the 30 end of a 328 bp STAT3 promoter construct that includes
the miR551b-3p complementary site and the TWIST1 site, as
well as other TF sites near the miR551b-3p complementary
site (Figure 5F). The biotinylated STAT3 promoter fragment
was incubated with control miRNA (control miR), miR551b-3p,
or mutant miR551b-3p. The promoter-miRNA complexes were
then incubated with IGROV1, HEYA8, or SKOV3 cell lysates.
Streptavidin beads were used to purify the complexes, which
were then immunoprecipitated using an AGO1 antibody. West-
ern blotting of the biotinylated DNA-miRNA complex demon-
strated that miR551b-3p, but not control miR or mutated
miR551b-3p, associated with the STAT3 promoter fragment
formed a complex including Argonaute, Pol II, and TWIST1
(Figures 5G and S5A). Although knockdown of STAT5B in-
hibited miR551b-3p-mediated promoter activity (Figure 5E), we
were not able to detect STAT5B in the DNA-miRNA complex.
We next determined whether miR551b-3p was required for the
formation of the AGO1, Pol II, and TWIST1 complex. Immunopre-
cipitation of Pol II protein from nuclear extracts of SKOV3 or
HEYA8 cells treated with anti-miR551b demonstrated reduced
association of TWIST1 with the AGO1/Pol II complex (Figure 5H).
Together, our results support the notion that miR551b-3p
expression regulates the interaction of TWIST1 with the
STAT3 transcription activation complex. Two small interfering
RNAs (siRNAs) targeting TWIST1 disrupted miR551b-3p-
induced increases in STAT3 expression (Figure 5I), demon-
strating TWIST1 is required for miR551b-3p-induced STAT3
expression. Knockdown of either STAT3 or STAT5B decreasedase-3 antibody. Positive cells were quantified from tumor tissues isolated from
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Figure 3. miR551b-3p Regulates STAT3 Expression
(A) SKOV3, IGROV1, and IOSE80 cells were transfected with control (Con.) miR or miR551b-3p in three independent experiments, and effects on protein levels
were determined by RPPA 48 hr later. Proteins with greater than 20% change in expression are represented in the heatmap.
(B) RNA was extracted from the samples described in (A). Relative expression of STAT3 was analyzed by qRT-PCR and normalized to b-actin.
(C) Immunoblot analysis of STAT3 expression and 3q26.2 copy-number status of indicated cell lines.
(D and E) Cells transfected with Con. Anti-miR or anti-miR551b-3p were lysed 72 hr after transfection, and immunoblotting was performed with the indicated
antibodies (D). Extraneous lanes were removed for clarity in (D). The number of spheroids formed on matrix-deprived conditions was quantified 5 days after anti-
miR transfection (E).
(F) Cells were grown under matrix-deprived conditions and then transfected with Con. miR or miR551b-3p. The number of spheroids was quantified and then re-
plated serially at 5-day intervals after miRNA transfection. Spheroids were re-transfected with Con. miR or miR551b-3p during serial passages.
Bars represent SD of three independent experiments. #p < 0.002 and *p < 0.001 compared to respective controls, as assessed by Student’s t test.
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Figure 4. Knockdown of STAT3 Abolishes miR551b-3p-Mediated Cell Growth
(A) SKOV3 or HEYA8 cells stably expressing control or two shRNA-targeting STAT3 sites were lysed and immunoblotted using indicated antibodies.
(B and C) Two clones of STAT3 knockdown cells were transfected with control anti-miR or anti-miR551b-3p. Cell proliferation assessed on day 3 using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (B), and number of spheroids formed on low-attachment plates was assessed on day 5 (C). Bars
represent SD of three independent experiments.
(D) STAT3 protein level was quantified in 145 HGSEOC patient samples using IHC. Scale bar represents 200 mm. Representative samples from each group are
displayed.
(E) Kaplan-Meier plot of overall survival of 145 ovarian cancer patients stratified by high (red, combination of moderate and strong staining) versus low (blue)
STAT3 expression. Log rank test was used to compare differences between the two groups.TWIST1mRNA, consistent with a regulatory loop wherein STAT3
and STAT5B regulate TWIST1 levels and TWIST1 in turn acti-
vates STAT3 transcription (Figures S5B and S5C).
Furthermore, biotinylated miR551b-3p, but not mutant
miR551b-3pmixed with sonicated IGROV1 DNA extracts, pulled
down the STAT3 promoter (Figures S5D and S5E), again sug-
gesting direct interaction of miR551b-3p with the STAT3 pro-
moter. Thus, our results demonstrate that a miR551b-3p and
AGO1 complex enhances the recruitment of Pol II and TWIST1
TF to the STAT3 promoter.
In an independent approach, we cloned 172 bp of the STAT3
promoter containing the miR551b-3p complementary site and
TWIST1 binding site into a thymidine kinase minimal promoter
in the pGLuc reporter vector. miR551b-3p, but not mutant
miR551b-3p, increased activity of the STAT3 promoter (Fig-
ure S6). Strikingly, mutation of the miR551b-3p complementary
site or the TWIST1 binding site abolished miR551b-3p-mediated
STAT3 promoter activity (Figure S6).Together, our results demonstrate an unexpected role for
miR551b-3p, wherein miR551b-3p directly binds to the STAT3
promoter, which in turn facilitates the recruitment of Pol II and
TWIST1 to the promoter contributing to increased STAT3 tran-
scription (Figure 6J).
Silencing of miR551b-3p Inhibits Ovarian Cancer Tumor
Growth in Nude Mice
To explore the potential utility of miR551b-3p as a therapeutic
target in ovarian cancers with miR551b amplification and over-
expression, we established luciferase-labeled HEYA8 cells in
the peritoneal cavity of nude mice. Mice were treated with anti-
miR551b-3p incorporated in neutral nanoliposomes (DOPC)
(Chaluvally-Raghavan et al., 2014; Landen et al., 2005) twice a
week for 4 weeks. As expected from our in vitro studies, treat-
ment with anti-miR551b markedly decreased tumor growth (Fig-
ures 6A and 6B), tumor weight (Figure 6C), and number of tumor
nodules (Figure 6D). Anti-miR551b, but not control anti-miR,Cell Reports 15, 1493–1504, May 17, 2016 1499
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Figure 5. miR551b-3p Promotes the Interaction of TWIST1-AGO1 Complex in the STAT3 Promoter
(A) The STAT3 promoter, including 962 bp upstream of the transcription start site (TSS), was cloned in the pLight luciferase reporter. The construct was co-
transfected with control (Con.) miR or miR551b-3p into IGROV1 cells and luciferase activity was assessed (bottom). Bars represent SD of quadruplicates.
(B) miR551b-3p sequence complementarity with the STAT3 promoter sequence (530 to 503 bp upstream of the TSS).
(C) Four mutant STAT3 promoters were constructed as indicated in blue boxes or the loop in (B).
(D) Mutant STAT3 promoter constructs were co-transfected with Con. miR or miR551b-3p into IGROV1 cells, and luciferase activity was assessed. Bars
represent SD of triplicates.
(E) IGROV1 cells were transfected with the indicated siRNAs. The STAT3 promoter cloned in the pLight luciferase reporter was co-transfected with Con. miR or
miR551b-3p into IGROV1 cells 24 hr after siRNA transfection. Luciferase activity was assessed 48 hr after transfection of the reporter vector. Bars represent SD of
triplicates.
(F and G) Scheme of the assay used to hybridize and pull down the biotinylated STAT3 promoter fragment incubated with Con. miR, miR551b-3p, or mutant
miR551b (F). The promoter-miRNA complex was incubated with IGROV1 cell lysates and immunoprecipitated 72 hr later with Con. IgG or anti-AGO1. DNase was
used to degrade the indicated samples. Total lysate or AGO1 immunoprecipitates were western blotted with the indicated antibodies (G). Total lysate represents
one-tenth the amount in the immunoprecipitates.
(H) HEYA8 or SKOV3 cells were transfected with either Con. anti-miR or anti-miR551b-3p. Nuclear extract was prepared, and immunoprecipitation was per-
formed using Pol II-specific antibodies and immunoblotted using the antibodies indicated.
(I) IGROV1 cells were transfected with the indicated siRNAs. RNAwas extracted 48 hr after transfection. Relative expression of STAT3was analyzed by qPCR and
normalized to b-actin. Bars represent SD of three independent experiments.
The p values were determined by Student’s t test. *p < 0.001 and #p < 0.005 compared to the wild-type group transfected with miR551b-3p.decreased levels of both miR551b-3p and STAT3 transcripts
(Figures 6E and 6F). Consistent with the effects of anti-
miR551b on the growth of ovarian cancer cells, our results
demonstrate that anti-miR551b increased levels of apoptotic
cell death markers: cleaved poly ADP ribose polymerase and
cleaved caspase-3 (Figure 6G). Anti-miR551b also reduced
expression of the Ki67 proliferation marker in tumor tissues (Fig-
ures 6H and 6I). Together, our results demonstrate the therapeu-
tic potential of anti-miR551b in treating ovarian cancers with high
levels of miR551b-3p. Future studies will need to examine the1500 Cell Reports 15, 1493–1504, May 17, 2016activity of combination therapy of anti-miR551b with other ther-
apeutic interventions.
DISCUSSION
Wehave previously demonstrated that the 3q26.2 amplicon con-
tains several oncogenes, including PIK3CA, PKCi, and MECOM
(Eder et al., 2005; Nanjundan et al., 2007; Shayesteh et al.,
1999). In a recent study, we demonstrated that miR569, located
in the 3q26.2 amplicon, downregulates the tumor suppressor
10
20
30
40
16
18
20
22
24
BA
0 7 14 21 28
0
5
10
15
20
25
30
35
40
45
Days
Con. antimiR
anti-miR551b
*p<0.005
*
*
*
C
0
5
10
15
p<0.01
0
2
4
6 p<0.005
D
0
2
4
6
8
10
12 p<0.001
0
40
80
120
160 p<0.001
I
0
20
40
60
80
Con. 551bantimiR:
p<0.001
Caspase-3
Ras GAP
STAT3
Cl.Caspase-3
PARP
Cl. PARP
G
E F
H
STAT3
Process
STAT3 Pro-oncogenicpathways
Action
J
Figure 6. Liposomal Delivery of Anti-miR551b-3p Reduces Tumor Burden and Downregulates STAT3 In Vivo
(A) HEYA8 cells (2.5 3 105 cells/animal) that stably express luciferase reporter genes were injected into the peritoneal cavity of nude mice (n = 10). Mice were
treated with control (Con.) anti-miR or anti-miR551b-3p encapsulated in DOPC nanoliposomes. Bioluminescence imaging was performed on day 28, and the
images of five representative mice from each group are displayed. The color scale bars depict photon fluxes emitted from the tumor cells.
(B) Luminescence intensity was quantified (n = 10) on the indicated days. Bars represent SE. Significance was determined by two-way ANOVA test.
(C and D) Tumor nodules were isolated on day 28. Total tumor weight (C) and numbers of abdominal tumors (D) were calculated.
(E and F) RNA was extracted from three representative tumor samples from each group. Relative expression of miR551b-3p (E) and STAT3 (F) was analyzed by
qRT-PCR and normalized to U6 RNA or b-actin, respectively.
(G) Tumor tissues from five separate tumors (A) were lysed, and immunoblotting was performed using the indicated antibodies.
(H and I) In vivo effects of anti-miR551b-3p treatment on tumor cell proliferationwere determined by Ki67 IHC (H). Ki67-positive cells were quantified in three fields
from the tumor tissues isolated from three mice from each group (I). Scale bar represents 100 mm.
(J) A two-step model illustrates the process of how STAT3 is regulated by miR551b-3p and the action of STAT3.
The p values were determined by Student’s t test.
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TP53INP1 and increases growth and survival of ovarian cancer
cells (Chaluvally-Raghavan et al., 2014). In this study, we de-
monstrate that the 3q26.2 amplicon also leads to increased
miR551b-3p expression, with subsequent STAT3 induction
that contributes to cell proliferation and survival.
RNA activation, wherein miRNAs increase transcription of
target genes (Li et al., 2006), has been reported for E-cadherin,
p21, vascular endothelial growth factor, and progesterone re-
ceptor (Huang et al., 2010; Place et al., 2008; Portnoy et al.,
2011). Further studies of miRNA immunoprecipitation followed
by deep sequencing revealed that AGO complex-bound small
RNAs are enriched in promoter regions of many genes (Cernilo-
gar et al., 2011). A report suggests that AGO1 interacts with Pol II
at active promoters throughout the genome (Huang et al., 2013).
In this study, we have identified an unexpected action of
miR551b-3p, wherein it activates STAT3 transcription by direct
interaction with the STAT3 promoter, increasing recruitment of
the TWIST1 TF and Pol II. This process appears to represent
a key mechanism regulating STAT3 transcription in ovarian can-
cer. Further studies are required to determine whether miR551b-
3p alters transcriptional activation of other genes that, along with
STAT3, combine to mediate the effects of miR551b-3p on
ovarian cancer pathophysiology. Databases such as microPIR
(Piriyapongsa et al., 2012) can identify predicted miRNA target
sites located within promoter regions of human genes, facili-
tating this effort. However, these database searches will need
to be confirmed experimentally, because the effects of miRNA
on different genes could depend on complementarity in the pro-
moter region, as well as organization and occupancy of TF bind-
ing sites located near the potential miRNA binding sites (Portnoy
et al., 2011).
We explored the potential effects of miR551b-3p on down-
regulation of RNA function through binding to consensus se-
quences in 30 UTRs of mRNAs. However, we failed to de-
monstrate marked effects of miR551b-3p on potential mRNA
targets identified as having consensusmiR551b-3p binding sites
in their 30 UTRs through database searches. Furthermore,
knockdown of the mRNA modulated by miR551b-3p failed to
recapitulate the functional effects of miR551b-3p on cells. How-
ever, we have not excluded the possibility that miR551b-3p
regulates mRNA stability or translation through canonical mech-
anisms involving binding to 30 UTRs of mRNAs. These effects of
miR551b-3p could, in turn, indirectly regulate the action of
miR551b-3p on the STAT3 promoter or contribute to the func-
tional effects of miR551b-3p by altering the activity of other
pathways.
The ability of miRNAs to concurrently downregulate stability or
transcription of mRNAs and upregulate expression of target
genes supports the concept that miRNAs have the ability to
fine-tune the effects of TFs in controlling protein levels. The abil-
ity to alter protein levels through multiple mechanisms has the
potential to allow miRNAs to coordinately regulate critical
phenotypic outcomes.
Our results support the concept that targeting miR551b
expression, using anti-miR, could block STAT3 activity and pro-
vide a useful therapeutic avenue for treating human ovarian can-
cers harboring the 3q26.2 amplification. STAT3 plays a role in
physiological responses, including differentiation, cell survival,1502 Cell Reports 15, 1493–1504, May 17, 2016and metastasis, supporting a therapeutic opportunity (Levy
and Darnell, 2002). Furthermore, metabolic rewiring and shift in
glutamine levels upregulate STAT3, with a concomitant change
in growth and metastatic capacity of ovarian cancer cells
(Yang et al., 2014). Based on our results, anti-miR nanolipo-
some-based therapeutic approaches warrant evaluation as ap-
proaches to improve outcomes for ovarian cancer patients.
Such clinical trials are progressing at the MD Anderson Cancer
Center.
EXPERIMENTAL PROCEDURES
Patient Samples
After informed consent, serous epithelial ovarian cancer tissueswere collected
according to an institutional- review-board-approved protocol at the MD An-
derson Cancer Center.
RNA Isolation and miRNA Detection
Total RNA from cultured cells, with efficient recovery of small RNAs, was iso-
lated using themirVanamiR Isolation Kit (Ambion). Detection of mature miRNA
was performed using cDNA generated with the QIAGEN miScript kit and sub-
sequent qRT-PCR analysis with SYBR Green I (QIAGEN) according to manu-
facturers’ instructions. Primers specific to mature miRNA-3p and miRNA-5p
sequences were purchased from QIAGEN. Primers to the U6 small nuclear
RNA from QIAGEN were used as an internal normalization control.
miRNA Transfection
The miRIDIAN miRNA mimics from Dharmacon and anti-miR from Ambion
were transfected using Lipofectamine RNAi Max from Invitrogen. Anti-
miR551b indicates anti-miRNAs targeting mature miRNA miR551b-3p in this
study unless indicated otherwise. Mature sequences of the miRNAs used
in this study are as follows: miR551b-3p: 50-GCGACCCAUACUUGGUUU
CAG-30; miR551b-5p: 50-GAAAUCAAGCGUGGGUGAGACC-30; control miR:
50-UCACAACCUCCUAGAAAGAGUAGA-30; and mutated miR551b-3p: 50-
GCGUGGGAUACAACCUUUCAG-30.
Analysis of Public Gene Expression Datasets
TCGA ovarian cancer SNP, mRNA data and TCGA breast cancer RPPA, and
clinical data were downloaded from the TCGA Data portal (http://tcga-data.
nci.nih.gov/tcga/findArchives.htm). The CNTools package from Bioconductor
(http://www.bioconductor.org/) was used to process SNP data. The Cox pro-
portional hazard regression model was used for univariate survival analysis.
Overall survival or recurrence-free survival were used as endpoints. The cut-
offs of high expression and low expression were optimized to achieve the
lowest p value. Statistical analysis was performed using R software.
Copy-Number Analysis
The gene lists for human chromosome 3q26.1 to 3q26.3 were downloaded
from the UCSC Genome Browser website (http://genome.ucsc.edu/cgi-bin/
hgTables; GRCh37/hg19). DNA CNA data, generated with the Agilent Sure-
Print G3 Human CGH Microarray Kit 1 3 1 M platform, were downloaded
from the cBio Portal (http://www.cbioportal.org/). CNA calls were made using
GISTIC 2.0 as 2 for homozygous deletion, 1 for hemizygous deletion, 0 for
no change, 1 for gain of copy number, and 2 for amplification (Mermel et al.,
2011).
Promoter Hybridization and Pull-Down Assay
Promoter fragments were biotinylated using Purebiotech Kit, denatured, hy-
bridized with miR551b-3p or mutant miR551b-3p at 60C for 2 hr, and then
incubated with 500 mg of nuclear lysate IGROV1 cell lysates for 6 hr. Samples
were fixed in formaldehyde (1%) for 10 min and quenched with glycine
(125 mM). Biotinylated promoter fragments were enriched using streptavi-
din-conjugated beads. Beads were washed with ice-cold NT2 buffer five times
and incubated at 90C for 5 min, and elutes were immunoprecipitated using
AGO1 antibody (Wako). The beads were washed with ice-cold NT2 buffer five
times and then boiled with 23 Laemmli loading buffer.
In Situ Hybridization and Immunofluorescence Staining
In situ hybridizationwas performed as described previously (Rupaimoole et al.,
2016). Formalin-fixed, paraffin-embedded tissue sections were de-paraffi-
nized and re-hydrated. Tissues were then digested with 15 mg/mL Proteinase
K for 20 min at room temperature and loaded onto Ventana Discovery Ultra for
in situ hybridization. Tissue slides were incubated with double-digoxigenin
(DIG)-labeled mercury LNA miRNA probe (Exiqon) for 2 hr at 55C. H2O2
was used to inactivate endogenous peroxidases. Polyclonal anti-DIG antibody
and horseradish peroxidase-conjugated secondary antibody (Ventana) were
incubated with the slide. Tyramide-signal amplification (TSA) reaction was per-
formed for 12 min. Slides were mounted with anti-fading ProLong Gold Solu-
tion (Life Technologies).
Statistical Analyses
Microsoft Excel or GraphPad Prism was used to analyze data. Statistical anal-
ysis was performed using Student’s t test, two-way ANOVA, or log rank test, as
indicated in the figure legends. In the analysis, p < 0.05 was considered statis-
tically significant. Data are presented asmean ±SD ormean ±SE, as indicated
in the figures. The Cox proportional hazard regression model was used for uni-
variate survival analysis. Statistical analysis was performed using R software.
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